公开(公告)号：WO2023092089A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/080167

申请日：2022-11-18

Applicant: KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY) ,  K2B THERAPEUTICS, INC.

Inventor： KIM, HoWon J. ,  KIM, In-San ,  KIM, Jay S. ,  KIM, Sun Hwa ,  KWON, Ick Chan ,  LEE, Jong Won ,  YANG, Yoo Soo ,  YOON, Hong Yeol

IPC: A61K47/68 ,  A61P35/00

Abstract: Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell, a virus-infected cell, or a fibrotic cell.

公开(公告)号：EP4197559A1

公开(公告)日：2023-06-21

申请号：EP20949578.7

申请日：2020-08-14

Applicant: Korea Institute of Science and Technology

Inventor： KIM, Sun Hwa ,  KWON, Ick Chan ,  KIM, In-San ,  KIM, Kwangmeyung ,  YANG, Yoosoo ,  KO, Young-ji

IPC: A61K47/64 ,  A61K47/65 ,  A61K31/713 ,  A61P35/00 ,  C12N15/115

Abstract: A fusion protein-siRNA complex according to the present disclosure binds specifically to cancer cells, is taken up effectively by the cells, and exhibits anticancer activity as it is degraded by lysosomes. The fusion protein-siRNA complex provides maximized anticancer activity so that the cancer cells can be removed by autoimmunity, by inhibiting the immunity of the cancer cells and enhancing phagocytosis by macrophages.

公开(公告)号：EP4340893A1

公开(公告)日：2024-03-27

申请号：EP22844608.4

申请日：2022-11-18

Applicant: KIST (Korea Institute of Science and Technology) ,  K2B Therapeutics, Inc.

Inventor： KIM, HoWon J. ,  KIM, In-San ,  KIM, Jay S. ,  KIM, Sun Hwa ,  KWON, Ick Chan ,  LEE, Jong Won ,  YANG, Yoo Soo ,  YOON, Hong Yeol

IPC: A61K47/68 ,  A61P35/00

公开(公告)号：EP4467133A1

公开(公告)日：2024-11-27

申请号：EP23743538.3

申请日：2023-01-20

Applicant: Korea Institute of Science and Technology

Inventor： YANG, Yoosoo ,  KIM, Sun Hwa ,  HAN, Geonhee ,  JANG, Yeongji ,  KIM, Hyosuk ,  CHO, Haeun

IPC: A61K9/50 ,  A61K31/713 ,  A61K31/711 ,  A61K31/7105 ,  A61K9/19 ,  A61P1/00 ,  A61K35/20 ,  A61P29/00

Abstract: The present invention relates to a composition for improving intestinal health and function comprising: a milk-derived exosomes; and a therapeutic agent, wherein the therapeutic agent is DNA, RNA, or a small molecule, and the therapeutic agent is positioned and encapsulated in spaces inside the exosomes. In addition, provided is a method for manufacturing a composition for improving intestinal health and function, the method comprising the steps of: (a) isolating exosomes from milk; (b) forming micropores on the surfaces of the exosomes by subjecting the separated exosomes to electroporation; (c) mixing the exosomes that have undergone electroporation in step (b) with a therapeutic agent; and (d) removing therapeutic agent which has not been encapsulated inside the exosomes.

公开(公告)号：EP4066816A1

公开(公告)日：2022-10-05

申请号：EP20893422.4

申请日：2020-11-27

Applicant: Korea Institute of Science and Technology ,  HB Advisors

Inventor： KIM, Sun Hwa ,  YANG, Yoosoo ,  KIM, Hyo Suk ,  KWAK, Gi-Jung ,  JANG, Ye Ji

IPC: A61K8/98 ,  A61Q19/00 ,  A61Q19/08 ,  A61Q19/02 ,  A61Q5/02 ,  A61Q7/00 ,  A23L33/10 ,  A61K35/20 ,  A61P17/02

Abstract: The present invention relates to a novel use of milk exosomes, and more specifically, provides various uses of milk exosomes, such as in functional cosmetics, functional health food with various functions such as improving gut health and immunity, and drugs including a wound healing medication.